BFRI
Biofrontera Inc

8,700
Mkt Cap
$10.76M
Volume
84,917.00
52W High
$1.19
52W Low
$0.536
PE Ratio
-0.51
BFRI Fundamentals
Price
$0.8948
Prev Close
$0.9241
Open
$0.8901
50D MA
$0.8366
Beta
0.65
Avg. Volume
932,620.79
EPS (Annual)
-$3.22
P/B
-4.17
Rev/Employee
$401,301.08
$5.02
Loading...
Loading...
News
all
press releases
Biofrontera Inc. (BFRI) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Biofrontera Inc. (BFRI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Zacks·27d ago
News Placeholder
More News
News Placeholder
Is Biofrontera Inc. (BFRI) Stock Outpacing Its Medical Peers This Year?
Here is how Biofrontera Inc. (BFRI) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.
Zacks·27d ago
News Placeholder
Biofrontera Earnings Preview
read more...
Benzinga·4mo ago
News Placeholder
Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Lags Revenue Estimates
Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of -3.70% and -75.13%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
Lifecore Biomedical (LFCR) Reports Q1 Loss, Beats Revenue Estimates
Lifecore Biomedical (LFCR) delivered earnings and revenue surprises of +3.33% and +16.60%, respectively, for the quarter ended August 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates
Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of +58.54% and +50.85%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
PTC Therapeutics (PTCT) Q3 Earnings and Revenues Top Estimates
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of +116.81% and +20.17%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
Lineage Cell (LCTX) Reports Q2 Loss, Beats Revenue Estimates
Lineage Cell (LCTX) delivered earnings and revenue surprises of +50.00% and +75.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·7mo ago
News Placeholder
Pacific Biosciences of California (PACB) Reports Q2 Loss, Beats Revenue Estimates
Pacific Biosciences (PACB) delivered earnings and revenue surprises of +27.78% and +9.06%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·7mo ago
News Placeholder
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates
Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of -45.45% and +9.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·7mo ago
<
1
2
...
>

Latest BFRI News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.